AE Wealth Management LLC Grows Stock Position in Gilead Sciences, Inc. $GILD

AE Wealth Management LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 24.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 43,873 shares of the biopharmaceutical company’s stock after acquiring an additional 8,554 shares during the period. AE Wealth Management LLC’s holdings in Gilead Sciences were worth $4,870,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC purchased a new position in Gilead Sciences in the 4th quarter worth $215,000. Sivia Capital Partners LLC raised its stake in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 602 shares during the last quarter. Pure Financial Advisors LLC lifted its position in Gilead Sciences by 33.6% during the 2nd quarter. Pure Financial Advisors LLC now owns 4,640 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 1,167 shares during the period. Finally, Triad Wealth Partners LLC purchased a new stake in Gilead Sciences during the 2nd quarter valued at about $205,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total value of $1,398,900.00. Following the completion of the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at $77,876,483.22. This trade represents a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 257,397 shares of company stock worth $33,385,512. 0.27% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on GILD. Scotiabank started coverage on Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price objective for the company. HSBC increased their price target on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a report on Wednesday, December 10th. Morgan Stanley reduced their price target on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, January 13th. Sanford C. Bernstein set a $135.00 price objective on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Finally, Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a research note on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $141.95 on Friday. The company has a market capitalization of $176.11 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The company’s fifty day moving average price is $125.36 and its 200 day moving average price is $119.67. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $142.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.02 earnings per share. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.